Johnson & Johnson Reaches Largest Australian Product-Liability Class…
In September 2022, Johnson & Johnson reached a $204.90 million (A$300 million) settlement in two Australian class action…
Monthly Publications
In Depth
Subscribe Now
In Depth
coverage of timely
Life Science
Compliance issues
Subscribe Now
Yearly Archives
2022
Biden Administration Provides Update on Opioid Crisis Funding
In late September 2022, United States President Joe Biden released a statement regarding what his administration has done to help…
Turquoise Health Publishes Price Transparency Impact Report
On October 18, 2022, Turquoise Health published its Price Transparency Impact Report, which outlines the healthcare industry’s…
Biden Issues Executive Order on Drug Prices
On October 14, 2022, United States President Joe Biden issued an Executive Order on Lowering Prescription Drug Costs for…
Teva Reaches Settlement with Two More States Over Price-Fixing Allegations
On September 30, 2022, Teva Pharmaceuticals, reached an agreement with Chris Carr, the Attorney General of Georgia, to settle the…
Pfizer Seeking to Rewrite Anti-Kickback Interpretations
In October 2022, Pfizer filed a petition with the Supreme Court of the United States, seeking to overturn a lower court decision…
HHS OIG Finds that NIH Fails to Hold Researchers Accountable
The US Department of Health and Human Services (HHS) Office of Inspector General (OIG) says the National Institutes of Health…
DOJ Announces $1.2 Million Settlement with Respironics
On September 22, 2022, the United States Department of Justice (DOJ) announced a $1.2 million settlement with Philips RS North…
Drug Utilization Management Impacts Physician Treatment Decisions,…
A study recently published in PLOS ONE found that drug utilization management impacts physician treatment decisions and can lead…
The Importance of Private Funding to Biopharmaceutical Development
In early September 2022, a study was published regarding The Relative Contributions of NIH and Private Sector Funding to the…